In late 2019, a novel coronavirus (SARS-CoV-2) emerged in Wuhan, capital city of Hubei
province in China. Cases of SARS-CoV-2 infection quickly grew by several thousand per …

Since its first description, the acute respiratory distress syndrome (ARDS) has been
acknowledged to be a major clinical problem in respiratory medicine. From July 2015 to July …

Acute respiratory distress syndrome (ARDS) is a life-threatening inflammatory lung condition
associated with significant morbidity and mortality. Unfortunately, the current treatment for …

Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are characterized by
progressive lung impairment typically triggered by inflammatory processes. The mortality toll …

The lung microbiota have been found to be substantially altered in numerous pulmonary
disorders, and crosstalk between the host pathophysiology and lung microbiota plays critical …

Acute respiratory distress syndrome (ARDS) is essentially a clinical syndrome of
noncardiogenic pulmonary edema and hypoxia that contributes to significant morbidity and …

Bronchi are exposed daily to irritants, microbes and allergens as well as extremes of
temperature and acid. The airway mucosal epithelium plays a pivotal role as a sentinel …

Acute respiratory distress syndrome (ARDS) is a disease with a variety of causes and is
defined by severe hypoxemia. Whereas ARDS carries a mortality of approximately 30 …

The world entered the year 2020 with reports of the emergence of a new viral illness in
Wuhan city, Hubei province, China. In January 2020, severe acute respiratory syndrome …

Ongoing efforts are oriented towards the development of novel therapeutic agents to repress
lung hyperpermeability responses due to inflammation. The endothelial barrier dysfunction …